4,6-二氯-5-嘧啶羧酸 | 87600-98-4

• 物质功能分类: 医药中间体 - 杂环化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 中文名称: 4,6-二氯-5-嘧啶羧酸
• 中文别名: 4,6-二氯嘧啶-5-甲酸；4,6-二氯-5-嘧啶甲酸
• 英文名称: 4,6-dichloropyrimidine-5-carboxylic acid
• CAS: 87600-98-4
• 化学式: C₅H₂Cl₂N₂O₂
• mdl: MFCD09909611
• 分子量: 192.989
• InChiKey: KGBLYFGHJNGQBK-UHFFFAOYSA-N

物化性质

• 沸点：
  353.8±37.0 °C(Predicted)
• 密度：
  1.718±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  63.1
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 海关编码：
  2933599090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  室温

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
4,6-Dichloropyrimidine-5-carboxylic acid
Product Name:
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H315: Causes skin irritation
H319: Causes serious eye irritation
H335: May cause respiratory irritation
P261: Avoid breathing dust/fume/gas/mist/vapours/spray
Wear protective gloves/protective clothing/eye protection/face protection
P280:
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing
P304+P340: IF INHALED: Remove victim to fresh air and keep at rest in a position comfortable for breathing
P405: Store locked up

---

Section 3. Composition/information on ingredients.
4,6-Dichloropyrimidine-5-carboxylic acid
Ingredient name:
CAS number: 87600-98-4

---

Section 4. First aid measures
Immediately wash skin with copious amounts of water for at least 15 minutes while removing
Skin contact:
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.
Ingestion:

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels, refrigerated.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Not specified
Appearance:
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C5H2Cl2N2O2
Molecular weight: 193.0

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen chloride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  4,6-二氯-5-嘧啶羧酸 在 ammonium hydroxide 作用下， 以 水 为溶剂， 反应 12.0h， 生成 4-amino-6-chloropyrimidine-5-carboxylic acid
  参考文献：
  名称：

  一种4-氨基-2.6-二甲氧基嘧啶的合成方法

  摘要：

  本发明公开了医药技术技术领域的一种4‑氨基‑2.6‑二甲氧基嘧啶的合成方法。该合成方法包括如下步骤：(1)氨解反应：将4,6‑二氯嘧啶‑5‑甲酸投入到氨水中进行氨解反应，得到4‑氨基‑6‑氯嘧啶‑5‑甲酸；(2)氯化反应：将步骤(1)制得的4‑氨基‑6‑氯嘧啶‑5‑甲酸溶于稀酸水，然后加入氯化试剂氯化得到4‑氨基‑2,6‑氯嘧啶‑5‑甲酸；(3)脱羧反应：在溶剂中，将步骤(2)中制得的4‑氨基‑2,6‑氯嘧啶‑5‑甲酸经高温脱羧得到4‑氨基‑2,6‑氯嘧啶；(4)甲氧化反应：将步骤(3)制得的4‑氨基‑2,6‑氯嘧啶投入甲氧基化试剂中，经甲氧化反应得到4‑氨基‑2.6‑二甲氧基嘧啶。本发明采用新的合成路线，避免了大量的含磷废水的产生，本发明所提供的方法绿色环保，社会效益明显。

  公开号：

  CN110981816B
• 作为产物：
  描述：

  4,6-二氯-5-嘧啶甲醛 在 sodium chlorite 、 sodium dihydrogenphosphate 、 2-甲基-2-丁烯 作用下， 以 水 、 叔丁醇 为溶剂， 反应 4.0h， 以59%的产率得到4,6-二氯-5-嘧啶羧酸
  参考文献：
  名称：

  新型2,4,6-三取代-5-嘧啶羧酸作为过氧化物酶体增殖物激活的受体γ（PPARγ）部分激动剂的设计，合成和结构活性关系研究，具有与罗格列酮相当的抗糖尿病功效

  摘要：

  设计和合成了一系列新颖的2,4,6-三取代嘧啶-5-羧酸衍生物，目的是生产抗糖尿病药的过氧化物酶体增殖物激活受体γ（PPARγ）部分激动剂。药效团驱动的内部筛选方法可鉴定出化合物7，从而鉴定出具有2,4,6-三取代嘧啶-5-羧酸核的化合物9。9的构效关系研究确定了4,6-双苄硫基-2-甲基硫基嘧啶-5-羧酸（50）是所有筛选化合物中最有吸引力的。X射线共晶结构为50PPARγ上的键揭示了与激活功能2（AF-2）位点无关的关键氢键相互作用与完全激动剂的氢键相互作用不同。化合物50在PPARγ-GAL4功能试验中显示出典型的PPARγ部分激动剂特性，并且与罗格列酮相比在3T3-L1细胞中的脂肪细胞分化更弱。此外，尽管有50种药效比罗格列酮弱10倍，但在db / db小鼠中有50种与罗格列酮具有相当的抗糖尿病功效。

  DOI：

  10.1021/jm100443s

文献信息

• [EN] PYRROLOTRIAZINONE DERIVATIVES AS PI3K INHIBITORS<br/>[FR] DÉRIVÉS DE PYRROLOTRIAZINONE EN TANT QU'INHIBITEURS DES PI3K
  申请人：ALMIRALL SA

  公开号：WO2014060432A1

  公开（公告）日：2014-04-24

  New pyrrolotriazinone derivatives having the chemical structure of formula (I), are disclosed; as well as process for their preparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of Phosphoinositide 3-Kinases (PI3Ks)

  新的吡咯三唑酮衍生物具有化学结构式（I），公开；以及它们的制备方法，包括它们的药物组合物和它们作为磷脂酰肌醇3-激酶（PI3Ks）抑制剂在治疗中的应用。
• [EN] 2-CYANOISOINDOLINE DERIVATIVES FOR TREATING CANCER<br/>[FR] DÉRIVÉS DE 2-CYANOISOINDOLINE POUR LE TRAITEMENT DU CANCER
  申请人：MISSION THERAPEUTICS LTD

  公开号：WO2017158388A1

  公开（公告）日：2017-09-21

  The invention relates to novel compounds of formula I which are inhibitors of deubiquitylating enzymes (DUBs) and/or desumoylating enzymes. In particular, the invention relates to the inhibition of ubiquitin C-terminal hydrolase 7 or ubiquitin specific peptidase 7 (USP7). The invention further relates to methods for the preparation of these compounds and to their use in the treatment of cancer.

  这项发明涉及公式I的新化合物，这些化合物是去泛素化酶（DUBs）和/或去泛素化酶的抑制剂。具体来说，该发明涉及抑制泛素C端水解酶7或泛素特异性肽酶7（USP7）。该发明还涉及这些化合物的制备方法以及它们在癌症治疗中的应用。
• [EN] ANTIVIRAL COMPOUNDS<br/>[FR] COMPOSÉS ANTIVIRAUX
  申请人：ALIOS BIOPHARMA INC

  公开号：WO2015026792A1

  公开（公告）日：2015-02-26

  Disclosed herein are new antiviral compounds, together with pharmaceutical compositions that include one or more antiviral compounds, and methods of synthesizing the same. Also disclosed herein are methods of ameliorating and/or treating a paramyxovirus viral infection with one or more small molecule compounds. Examples of paramyxovirus infection include an infection caused by human respiratory syncytial virus (RSV).

  本文披露了新的抗病毒化合物，以及包括一种或多种抗病毒化合物的药物组合物，以及合成这些化合物的方法。本文还披露了使用一种或多种小分子化合物改善和/或治疗副粘病毒病毒感染的方法。副粘病毒感染的例子包括由人类呼吸道合胞病毒（RSV）引起的感染。
• CDPK1 INHIBITORS, COMPOSITIONS, AND METHODS RELATED THERETO
  申请人：Vyera Pharmaceuticals, LLC

  公开号：US20210347780A1

  公开（公告）日：2021-11-11

  The invention relates to inhibitors of calcium-dependent protein kinase 1 (CDPK1) and pharmaceutical preparations thereof. The invention further relates to methods of treatment of parasitic infections, such as T. gondii, P. falciparum, C. hominis , or C. parvum infections, using the novel inhibitors of the invention.

  该发明涉及钙依赖性蛋白激酶1（CDPK1）的抑制剂及其药物制剂。该发明进一步涉及使用该发明的新型抑制剂治疗寄生虫感染的方法，例如弓形虫、疟原虫、人类小肠球虫或小肠球小弓形虫感染。
• [EN] SUBSTITUTED AMINOPYRIMIDINE COMPOUNDS AND METHODS OF USE<br/>[FR] COMPOSÉS D'AMINOPYRIMIDINE SUBSTITUÉS ET PROCÉDÉS D'UTILISATION
  申请人：SUNSHINE LAKE PHARMA CO LTD

  公开号：WO2016149160A1

  公开（公告）日：2016-09-22

  The invention relates to the preparation and use of new aminopyrimidine derivatives as drug candidates in free form or in pharmaceutically acceptable salt form and formulations thereof for the modulation of a disorder or disease which is mediated by the activity of the PI3K enzymes. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of disorders or diseases, such as disorders of immunity and inflammation in which PI3K enzymes play a role in leukocyte function, and hyperproliferative disorders associated with PI3K activity, including but not restricted to leukemias and solid tumors, in mammals, especially humans.

  该发明涉及新的氨基嘧啶衍生物的制备和使用，作为候选药物，可以以自由形式或药用盐形式及其配方用于调节由PI3K酶活性介导的疾病或紊乱。该发明还提供了包含这种化合物的药用合成物和使用这些合成物治疗疾病或紊乱的方法，例如免疫和炎症紊乱，其中PI3K酶在白细胞功能中发挥作用，以及与PI3K活性相关的过度增殖性疾病，包括但不限于白血病和实体肿瘤，在哺乳动物，尤其是人类中。